In the late hours of June 1st, 2022, the team at Lifecare NanoBioSenors concluded successful, high quality and reproducible in-vitro test results with the miniaturized Sencell sensor for glucose measurement. This is a milestone achievement confirming functionality of Lifecares proprietary technology both in the nanoscale of the miniaturized sensors, as well as the signal readout based on the Nano Tunneling Resistive (NTR) pressure sensing.
…
Vis børsmeldingen
With this achievement Lifecare has reached the first of two major milestones for 1H 2022, the prototype fabrication for clinical trials. While the team at Lifecare NanoBioSensors will ensure manufacturing of sensors for the upcoming first-in-human pilot clinical study, Lifecare Laboratory will prepare the final steps for initiation of the study in June.
For Lifecare it is of particular importance that the current milestone achievement is reached fully based on the internal resources in the Lifecare Group. This is a strong confirmation of the successful strategic reorganization of Lifecare AS initiated in Q2 2021.
Lifecare CSO, Prof. Dr. Dr. Med. Andreas Pfützner, comments: “Reaching this milestone with our new own infrastructure and scientists is a groundbreaking science achievement for Lifecare! Our miniaturized NTR-sensors measure osmotic pressure with the same performance as the large piezo-resistive-sensors that we have used in the previous animal studies. Basic research is herewith accomplished, and we are now executing the last and final development steps required for the first in-human trial within a very short-term future.”
Preparations for the pilot clinical studies still includes both practical and scientific risks, i.e. the complexity of manual production and device sterilization. Based on the project experiences and preparations, Lifecare is confident that these tasks will be solved in accordance with the project plan and consequently lead to the first patient within end of June 2022.
Lifecare CEO, Joacim Holter, comments: “We are very happy to announce the achievement of this critical milestone within the planned scope of time. The core team in the Lifecare Group has worked with dedication and focus, and it is important for us to deliver this result to our solid base of shareholders. We look forward to the tasks ahead of us which we now will approach with renewed energy and confidence based on this practical and scientific milestone achievement”
This is Lifecare
Lifecare is a Bergen-based technology company developing a miniaturized implantable long-term sensor for correct and continuous monitoring of blood sugar in people with diabetes. The Company’s patented technology also has the potential for use in various biomarkers. Lifecare AS is listed on Euronext Growth (LIFE).
Further information
Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40
This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Kine Hereid, Investor Relations at Lifecare AS, on 2 June 2022 at 09:00 CET
Kilde
(Sannsynlig)